SCHEMBL11972849

SCHEMBL11972849

CCOC(=O)c1sc(N2CCOCC2)cc1Cc1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46
MAPT P10636 6/20 0.44
LMNA P02545 3/20 0.44
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
RAB9A P51151 1/20 0.44
PIK3CA P42336 1/20 0.43
GAA P10253 3/20 0.42
PRKDC P78527 1/20 0.42
ALDH1A1 P00352 6/20 0.42
KDM4E B2RXH2 5/20 0.42
HPGD P15428 3/20 0.42
HSD17B10 Q99714 2/20 0.42
KMT2A Q03164 1/20 0.42
KCNH2 Q12809 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.42
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12469238 0.82 MAPT (0.39) MAPTLMNAPIK3CAGAAPRKDC
SCHEMBL12469236 0.79 LMNA (0.41) MAPTLMNARAB9APIK3CAGAA
SCHEMBL624286 0.78 MAPT (0.48) MAPTLMNAPIK3CAGAAALDH1A1
SCHEMBL627395 0.76 PIK3CA (0.47) MAPTLMNAPIK3CAGAAALDH1A1
SCHEMBL11997711 0.76 DGAT1 (0.40) MAPTLMNAPIK3CAGAAPRKDC
SCHEMBL12469198 0.76 FFAR2 (0.39) MAPTLMNAPIK3CAGAAPRKDC
SCHEMBL624070 0.71 PIK3CD (0.45) MAPTPIK3CAGAAALDH1A1KDM4E
SCHEMBL11973421 0.70 FFAR2 (0.39) MAPTLMNATP53GAAALDH1A1
SCHEMBL625948 0.70 PKM (0.44) PDE3BPDE3AMAPTLMNANPC1
SCHEMBL623813 0.70 EGFR (0.43) MAPTLMNAPIK3CAGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150148334-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-05-28 US disclosed
US-20150148334-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-05-28 US disclosed
US-20150148334-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARM INC (US) 2015-05-28 US disclosed
US-8765746-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-8765746-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-8765746-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
EP-2627181-A2 HETEROARYLS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2013-08-21 EP disclosed
US-20120214794-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-08-23 US disclosed
US-20120214794-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-08-23 US disclosed
US-20120214794-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-08-23 US disclosed
WO-2012051410-A2 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-19 WO disclosed
WO-2012051410-A2 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148334-A1 HETEROARYLS AND USES THEREOF RICTOR, AKT2, MTOR PDE3B 1694/4885PDE3A 2937/4885MAPT 4553/4885
US-20120214794-A1 HETEROARYLS AND USES THEREOF RICTOR, AKT2, MTOR PDE3B 1694/4885PDE3A 2937/4885MAPT 4553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.